IDEAYA Biosciences, Inc.
IDYA
Rankning i aktier
#4510
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Aktiekurs
$35.54
Senast synkroniserad: 2026-10-20
Marknadsvärde
$3.43B
Förändring (1 dag)
5.12%
Förändring (1 år)
21.71%
Land
US
Handel IDEAYA Biosciences, Inc. (IDYA)
Kategori
Healthcare
Antal utestående aktier för IDEAYA Biosciences, Inc. (IDYA)
Antal utestående aktier per June 2026: 92.06M
Enligt de senaste finansiella rapporterna och aktiekursen för IDEAYA Biosciences, Inc. är det aktuella antalet utestående aktier 92.06M. I slutet av December 2023 hade företaget 57.52M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för IDEAYA Biosciences, Inc. (IDYA) från 2017 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 92.06M | 12.71% |
| 2024 | 81.68M | 42.00% |
| 2023 | 57.52M | 38.79% |
| 2022 | 41.44M | 17.57% |
| 2021 | 35.25M | 42.60% |
| 2020 | 24.72M | 22.18% |
| 2019 | 20.23M | 42.08% |
| 2018 | 14.24M | 0.00% |
| 2017 | 14.24M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 175.79% |
US
|
|
| 396.00M | 330.15% |
US
|
|
| 478.91M | 420.21% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -32.45% |
NL
|
